Business And Finance In Brief
Executive Summary
Merck and Schering-Plough - it's official: The ribbon is wrapped around the merger between the two companies. Shareholders of both approved the deal Aug. 7
You may also be interested in...
Chew On This: FDA OK's King's Tamper-Resistant Morphine, Embeda
Embeda to launch in September backed by 610 sales reps, Chief Commercial Officer Andrzejewski says.
Biovail Locks Up Global Rights To Xenazine With Cambridge Deal
The $230 million deal doubles Biovail's investment in Xenazine and is the latest indication that there is more to this is Huntington's chorea therapy than meets the eye.
Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning
Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins